Compare SLND & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLND | CVM |
|---|---|---|
| Founded | 1900 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.4M | 30.1M |
| IPO Year | 2021 | 1996 |
| Metric | SLND | CVM |
|---|---|---|
| Price | $0.67 | $1.46 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 574.3K | 203.9K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $772,168,000.00 | $264,033.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.59 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 65.45 |
| 52 Week Low | $0.51 | $0.89 |
| 52 Week High | $5.34 | $13.48 |
| Indicator | SLND | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 49.82 | 52.17 |
| Support Level | $0.64 | $0.98 |
| Resistance Level | $0.75 | $1.52 |
| Average True Range (ATR) | 0.08 | 0.14 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 63.84 | 51.94 |
Southland Holdings Inc is an infrastructure construction company in North America. The company's infrastructure projects range from water conveyance systems and tunnels to long-span bridges and vertical structures. The company operates in two distinct segments: Civil and Transportation. The civil segment operates throughout North America and specializes in services that include the design and construction of water pipelines, pump stations, lift stations, water and wastewater treatment plants, concrete and structural steel, outfall, and tunneling. The transportation segment operates throughout North America and specializes in services that include the design and construction of bridges, roadways, marine, dredging, ship terminals and piers, and specialty structures and facilities.
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.